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ABSTRACT
Objective To investigate any association between
selective serotonin reuptake inhibitors (SSRIs) taken
during pregnancy and congenital major malformations.
Design Population based cohort study.
Participants 493113 children born in Denmark, 1996-
2003.
MainoutcomemeasureMajormalformationscategorised
according to Eurocat (European Surveillance of
Congenital Anomalies) with additional diagnostic
grouping of heart defects. Nationwide registers on
medical redemptions (filled prescriptions), delivery, and
hospital diagnosis provided information on mothers and
newborns. Follow-up data available to December 2005.
Results Redemptions for SSRIs were not associated with
major malformations overall but were associated with
septal heart defects (odds ratio 1.99, 95% confidence
interval 1.13 to 3.53). For individual SSRIs, the odds ratio
for septal heart defects was 3.25 (1.21 to 8.75) for
sertraline, 2.52 (1.04 to 6.10) for citalopram, and 1.34
(0.33 to 5.41) for fluoxetine. Redemptions for more than
onetypeofSSRIwereassociatedwithseptalheartdefects
(4.70, 1.74 to 12.7)). The absolute increase in the
prevalence of malformations was low—for example, the
prevalence of septal heart defects was 0.5% (2315/
493113) among unexposed children, 0.9% (12/1370)
amongchildrenwhosemotherswereprescribedanySSRI,
and 2.1% (4/193) among children whose mothers were
prescribed more than one type of SSRI.
Conclusion There is an increased prevalence of septal
heart defects among children whose mothers were
prescribed an SSRI in early pregnancy, particularly
sertraline and citalopram. The largest association was
found for childrenof women who redeemed prescriptions
for more than one type of SSRI.
INTRODUCTION
Depression affects up to a fifth of pregnant women,
12
and medical treatment must balance maternal health
with potential adverse fetal effects such as congenital
malformations. Until 2005, most studies on selective
serotonin reuptakeinhibitors (SSRIs) found no associa-
tion with major malformations,
3-7 but recent studies
haveindicatedanincreasedprevalenceof,forexample,
omphalocele,
8 craniosynostosis,
8 and, more consis-
tently, heart defects.
8-14 The results on specific types of
SSRI are conflicting,
8-1012-14 but some research has sug-
gested an increasedrisk ofheartdefects,especiallywith
paroxetine
91214 but also sertraline, fluoxetine, and
citalopram.
6913The suspected risk of congenital heart
defectswas responsibleforthe 2005warningby the US
FoodandDrugAdministrationrelatedtotheuseofpar-
oxetine duringpregnancy.
15Weevaluatedassociations
between SSRIs during the first trimester of pregnancy
and major malformations in a large population based
cohort study.
METHODS
We used data from four Danish nationwide registries:
the medical birth registry,
16 the national register of
medicinal product statistics, the fertility database,
17
and the national hospital register.
18 The registries
werelinkedbytheuseoftheuniquepersonalidentifier
of 10 digits assigned to all citizens at birth.
The medical birth registry
16 stores data on all deliv-
eries, including maternalage, maternal smoking status
during pregnancy, parity, date of delivery, gestational
age, birth weight, sex of newborn, and information on
multiple pregnancy. Information on gestational age at
birth is usually estimated from ultrasound measures
during early pregnancy. In case of no ultrasound mea-
sure the last menstrual period is used. The initiation of
pregnancy was calculated by subtracting day of birth
by gestational age in days.
The register of medicinal product statistics holds
information on therapeutic drug sales, the personal
identifier, specification of the medication, and drug
classification code (the anatomical therapeutic chemi-
cal (ATC) classification system, World Health
Organization).
19 On redemption (that is, the filling of
a prescription), information from each prescription,
including date of redemption, is stored with the pur-
pose of financial compensation. All drugs included in
thisstudyaresoldbycertifiedpharmaciesaccordingto
prescriptions writtenby a doctor,andevery pharmacy
in Denmark reports to the register.
The fertility database
17 includes demographic infor-
mation on every person in the fertile age group in
1Department of Epidemiology,
Institute of Public Health, Aarhus
University, Bartolin Allé 2,
DK-8000 Aarhus, Denmark
2UCLA School of Public Health,
Department of Epidemiology,
650 Charles E Young Drive South,
Los Angeles, CA 90095-1772,
USA
3Department of Paediatrics,
Aarhus University Hospital, DK-
8200 Aarhus, Denmark
4Department of General Practice,
Institute of Public Health, Aarhus
University, Bartolin Allé 2,
DK-8000 Aarhus, Denmark
Correspondence to: Lars Henning
Pedersen, Department of
Epidemiology, Institute of Public
Health,AarhusUniversity,Bartolins
Allé 2, 8000 Aarhus C, Denmark
LHP@dadlnet.dk
Cite this as: BMJ 2009;339:b3569
doi:10.1136/bmj.b3569
BMJ | ONLINE FIRST | bmj.com page 1 of 6Denmark and their children. We calculated the com-
binedincome of the mother and fatherduring the year
of their child’s birth based on information in the data-
base. If information on income for both parents was
missing we used data from the previous calendar year.
The national hospital register
1820 holds information
on all admissions and outpatient hospital contacts in
the country. Each patient has a date of admittance
and ICD-10 (international classification of disease,
10th revision) coded diagnoses from the study period.
We included information from 1 January 1996 to 31
December2005.Malformationswerecodedaccording
to the Eurocat categorisation,
21 and congenital heart
defects were further categorised in developmentally
basedsubgroupsassuggestedbyLouiketal.
13Asinfor-
mation on malformations in stillborn children is
incompletely registered we included only liveborn
children in the analyses. We considered only malfor-
mations detected at birth or within the first year after
birth. We also performed additional analyses with
truncation after two years to investigate for potential
differences in time of diagnosis.
The exposure window was defined as 28 days before
to 112 days after the beginning of gestation. Exposure
was defined as two or more redemptions of an SSRI in
this time period (ATC codes N06AB). Women with
only a single redemption in the exposure window
were included in later analyses. We excluded women
with any redemption of insulin or antihypertensive
medications ina period ofthree months before the esti-
mated beginning of gestation and those with any
redemption during the exposure window to other
psychotropicmedications,suchasantiepilepticmedica-
tion, antipsychotics, and anxiolytics. Antidepressants
other than SSRIs, such as tricyclic antidepressants and
venlafaxine, were excluded from the main analysesbut
included in later sensitivity analyses.
We thus constructed a cohort consisting of all live-
born children in Denmark between 1 January 1996
and 31 December 2003 based on information from
the medical birth registry (n=553689). From these we
excluded 1213 children because of coding errors,
22045 because of emigration, 8388 because of expo-
sure to other psychoactive or antidiabetic drugs as
described above, and 21653 multiple births and 3509
stillbirths. The final study population comprised
496881 singleton liveborn children.
Statistical analyses were performed with Stata (ver-
sion 9, StataCorp, Texas, USA). We conducted multi-
ple logistical regressions on dichotomous outcomes
adjusted for maternal age (<20, 20-24, 25-29, 30-34,
≥35), calendar time (1996-8, 1999-2001, 2002-3), mar-
ital status (unmarried, married, divorced, widow),
income (three categories), and smoking (no/yes). Less
than 1% had missing values in these variables except
forsmoking(17%missing),andweperformedsensitiv-
ityanalyseswithoutthesmokingvariable.Significance
was defined as a two sided P value <5% and adjusted
odds ratios are provided with 95% confidence inter-
vals. Odds ratios were used to estimate relative preva-
lence rate ratios. We used causal diagrams (directed
acyclic graphs)toguide the selectionsof potentialcon-
founders to be controlled.
22 No adjustments were
made for multiple comparisons.
Table 1 |Odds ratios for malformations according to two or more redemptions for selective serotonin reuptake inhibitors
(SSRIs)
Birth defects
No of unexposed infants
(n=493 113)
SSRI (n=1370)
No of infants OR* (95% CI)
Minor 7373 39 0.88 (0.54 to 1.41)
Major 15 518 55 1.21 (0.91 to 1.62)
Central nervous system 597 1 —
Neural tube defects 180 0 —
Eye 418 1 —
Major cardiac malformations:
All 3988 16 1.44 (0.86 to 2.40)
Conotruncal heart defects 342 0 —
Right ventricular outflow tract obstructions 331 1 —
Left ventricular outflow tract obstructions 261 1 —
Septal heart defects 2315 12 1.99 (1.13 to 3.53)
Atrioventricular defects 198 0 —
Cleft lip with or without cleft palate 705 4 1.61 (0.60 to 4.30)
Cleft palate alone 300 2 2.65 (0.66 to 10.68)
Gastrointestinal 1260 3 0.92 (0.29 to 2.84)
Genital† 1144 1 —
Omphalocele 62 0 —
Diaphragmatic hernia 2 0 —
Gastroschisis 83 0 —
Craniosynostosis 370 2 0.96 (0.13 to 6.83)
*Adjusted for age, calendar year, income, marriage status, tobacco smoking.
†Hypospadia and undetermined sex.
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The finalstudypopulationcomprised496881liveborn
singletons.Forthesechildren,1370mothershadtwoor
moreredemptionsforindividualSSRIsintheexposure
window. These pregnancies were regarded as exposed.
In keeping with a previous study,
8 women taking an
SSRIweremorelikelytobe older,livingalone,unmar-
ried, and smokers (data not shown).
The combined prevalence of major malformations
(odds ratio 1.21, 95% confidence interval 0.91 to 1.62)
or non-cardiac malformations (1.12, 0.79 to 1.59) was
not significantly higher among exposed children, but
SSRI use was associated with an increased prevalence
of septal heart defects (1.99, 1.13 to 3.53) (table 1).
No specific SSRI was significantly associated with
major malformations overall or non-cardiac malforma-
tions (table 2). There was an increased prevalence of
septal heart defects for children of women who used
sertraline (3.25, 1.21 to 8.75) and citalopram (2.52,
1.04 to 6.10), but not fluoxetine (1.34, 0.33 to 5.41).
Among the 299 exposed to paroxetine we found one
septal heart malformation (crude odds ratio 0.76).
RedemptionofmorethanonetypeofSSRIintheexpo-
sure window was associated with heart malformations
(3.42, 1.40 to 8.34), particularly septal heart defects
(4.70, 1.74 to 12.7) (table 2).
In women with no recorded use of antidepressants,
1.2% redeemed a prescription for psychotropic medica-
t i o n ,c o m p a r e dw i t h1 6 %o fw o m e nw h oh a db e e np r e -
scribed an SSRI. The estimates remained virtually
unchanged,however,whenthesewomenwereincluded
in the analyses—f o re x a m p l e ,S S R Iu s ew a ss t i l la s s o -
ciated with septal heart defects (2.00, 1.41 to 2.85).
We found 84 womenwith twoor more redemptions
for tricyclic antidepressants and 91 for venlafaxine in
the exposure window. The numbers were too small to
allow for informative adjusted analyses—for instance,
we found three major malformations among the chil-
dren exposed to tricyclic antidepressants (crude odds
ratio 1.14, 0.23 to 3.45) and one among those exposed
to venlafaxine (0.35).
In subanalyses, we included women with one or
more redemptions for antidepressants. We found that
3010 women redeemed one or more SSRI, 265 for tri-
cyclic antidepressants, and 150 for venlafaxine. None
of the antidepressants were associated with the com-
bined prevalence of major malformations with the
less strict exposure definition (see table A on
bmj.com). Septal heart defects were associated with
any SSRI use (1.83, 1.22 to 2.75), in particular citalo-
pram (2.16, 1.12 to 4.17) and sertraline (2.01, 0.83 to
4.86), albeit the estimates of sertraline did not reach
significance (see table B on bmj.com). In eight
women prescribed fluvoxamine there were no
reported malformations. Again, the numbers were
toosmalltoallowinvestigationofassociationsbetween
tricyclic antidepressants or venlafaxine and specific
malformations (table A on bmj.com).
Analyses excluding information on smoking had
comparable results—for example, septal heart malfor-
mations were associated with sertraline (3.18, 1.18 to
8.56) and more than one SSRI (4.45, 1.65 to 12.0), but
the confidence interval for citalopram included zero
(2.36, 0.98 to 5.71).
Follow-up of the children for two years after birth
with regards to congenital malformation resulted in
similarresultstothe oneyearfollow-up—forexample,
an odds ratio of 1.70 (1.13 to 2.55) for SSRI and septal
heart malformations.
Asexpected,theabsolutedifferencesinprevalenceof
birthdefectswerelimited.Wefoundseptalheartdefects
in 12 (0.9%) children of women with one or more
redemption of SSRI, four (2.1%) children of women
who redeemed more than one type of SSRI (2.1%),
and 2315 (0.5%) children of unexposed women. The
prevalence of septal heart defects among the children
exposed to a specific SSRI was 0.6% for fluoxetine,
1.1% for citalopram, and 1.5% for sertraline (table 2).
Thus,theprevalenceofseptalheartdefectswas0.4per-
centagepointshigherforchildrenofwomenwithoneor
more redemption of SSRI compared with children of
unexposedwomen,correspondingtoanumberneeded
totreattoharm(NNH)of246.Thecorrespondingnum-
ber for children of women who redeemed more than
one type of SSRI was 62.
Table 2 |Odds ratios for malformations according to two or more prescriptions for individual selective serotonin reuptake inhibitors (SSRIs)*
Birth defects
No of
unexposed
infants
(n=493113)
Fluoxetine
(n=348)
Citalopram
(n=460)
Paroxetine
(n=299)
Sertraline
(n=259)
Morethanonetypeof
SSRI (n=193)
No of
infants
OR†
(95% CI)
No of
infants
OR†
(95% CI)
No of
infants
OR†
(95% CI)
No of
infants
OR†
(95% CI)
No of
infants
OR†
(95% CI)
Minor malformations 7373 4 0.62
(0.20to1.93)
70 . 7 9
(0.33to1.91)
61 . 4 3
(0.64to3.22)
30 . 7 6
(0.24to2.37)
41 . 0 8
(0.34 to 3.38)
Major malformations 15 518 11 1.00
(0.53to1.88)
17 1.07 (0.63 to
1.83)
15 1.41
(0.79to2.51)
12 1.51 (0.84 to
2.69)
10 1.62
(0.83 to 3.16)
Cardiac malformations 3988 2 0.77
(0.19to3.11)
61 . 7 5
(0.78to3.93)
30 . 8 8
(0.22to3.55)
52 . 3 6
(0.97to5.72)
53 . 4 2
(1.40 to 8.34)
Septal heart defects 2315 2 1.34
(0.33to5.41)
52 . 5 2
(1.04to6.10)
10 . 7 6
(0.11 to 5.43
43 . 2 5
(1.21to8.75)
44 . 7 0
(1.74 to 12.7)
Non-cardiac
malformations
11 530 9 1.08
(0.54to2.19)
11 0.83
(0.41to1.67)
12 1.59
(0.85to2.99)
71 . 1 8
(0.56to2.50)
50 . 9 5
(0.35 to 2.57)
*Four women used fluvoxamine only with no recorded malformations.
†Adjusted for age, calendar year, income, marriage status, tobacco smoking.
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In this population based cohort study we found that
septal heart defects were more prevalent in children
of women who redeemed a prescription for a selective
serotonin reuptake inhibitor (SSRI) in the first trime-
ster of pregnancy. Sertraline and citalopram, but not
paroxetine or fluoxetine, were associated with septal
heart defects, though the largest association was
found for redemption of more than one type of SSRI.
The suggested associations, if causal, represent limited
differences in prevalence. We found no associations
between SSRIs and non-cardiac malformations.
Comparison with other studies
Thefour mostcommonly usedSSRIs (fluoxetine, cita-
lopram, sertraline, and paroxetine) were associated
with septal heart defects. The various patterns in exist-
ing studies, however, are still confusing. A large US
case-control study found that sertraline was associated
withseptalheartdefects,
13andtheagreementwithdata
from a different population with a different study
design is reassuring for the validity of our results. A
study from Finland found no overall association with
major malformation (as in our study) but presented no
data on septal heart defects.
6 One population based
studyreportedanincreasedprevalenceofheartdefects
afteruseofcitalopraminthefirsttrimester.
23Wefound
no associations between paroxetine and heart defects
asshowninpreviousstudies
91214butthepreviousfind-
ingwasbasedononlyonechildwithseptalheartdefect
and we were unable to take dose into account.
12 As in
most previous studies, none of our results for fluoxe-
tine showed an odds ratio above two and none were
significant.
13 One recent study, however, found that
fluoxetine was associated with cardiovascular anoma-
lies, with an adjusted odds ratio of 4.47 (1.31 to
15.27).
24Inthatstudyover30%ofthewomenexposed
tofluoxetinealsousedbenzodiazepine,
24andthecom-
binationofanSSRIandbenzodiazepinehasbeenasso-
ciated with heart defects in a different study.
23 We
excluded from our study women with redemptions of
other psychotropic medications.
Use of more than one type of SSRI
Wefoundthehighestprevalenceofseptalheartdefects
among children of women who redeemed prescrip-
tions for more than one type of SSRI in the exposure
window. Redemptions for more than one SSRI might
representachangeintypeofSSRIorsimultaneoususe
ofdifferentSSRIs.Both scenariosmightresultinmore
pronounced effects on the serotonin transporter, as
change in type of SSRI might also result in a period
of overlap. Our result could show an additive effect
of the different types of SSRI, although confounding
by the indication cannot be ruled out.
Clinical implications
Treatment of depression during pregnancy balances
the risk of the medicine with that of the depression,
and we investigated only a part of the information
needed to make evidence based decisions. The
reported odds ratios represent small absolute differ-
ences in prevalence, and even if SSRI use is causally
relatedtoseptalheartdefects,theseheartdefectsmight
not necessarily require treatment and some might
resolve spontaneously. Some children with septal
heart defects, however, need to undergo an operation,
butwewereunabletoestimatetheproportionbecause,
for example, the operation might be performed years
after the end of our follow-up period.
Strengths and limitations of study
The information on drugs was recorded by skilled
pharmacists when the prescriptions were redeemed.
We used these redemptions as proxy measures for
exposure, which eliminates recall bias and increases
the precision of the information on type of anti-
depressant. Interview during pregnancy might result
in confusion of related names, such as sertraline and
Seroxat (paroxetine), and increased focus on one
drug could result in bias. This precision is essential
for the differentiation between specific types of SSRI
and would have been difficult if we had relied on
women’s reports. Our results, however, depend on a
correlation between redemptions of prescriptions and
druguse. Non-compliancemight bea problemfor this
type of exposure definition and could mask true asso-
ciations if some of the “exposed” were in fact unex-
posed. We considered two or more redemptions as
an indication of more certain exposure than one pre-
scription only. The main analyses with this more strict
exposure definition resulted in slightly stronger esti-
mates with the same pattern related to septal heart
defects, which is as expected if the drug had the side
effects under study. Use of antidepressant drugs with-
outprescriptionisunlikelyand,ifpresent,wouldresult
in underestimation of a true association.
Our choice of the exposure window allowed suffi-
cient time for two or more redemptions and was iden-
tical to the exposure window in the study by Louik
et al.
13 Additionally, our study wasdesigned to investi-
gate the potential association with various malforma-
tions with different windows of susceptibility, and as a
resulttheexposurewindowwaswiderthanneededfor
most malformations. With an exposure window wider
thanthesusceptibleperiodforconditionssuchasheart
defect, the women defined as exposed might actually
have been unexposed in the critical periods, which
could result in an underestimation of true associations
for various malformations. It does not explain the
reported associations with septal heart defects.
Thedisentanglementoftheeffectsoftreatmentfrom
the effect of the disease is a profound problem in phar-
macoepidemiological studies. We had no information
on the severity of the depression, and potential con-
founding by indication is impossible to rule out in a
non-randomised design. We were unable to carry out
comparisons with children of untreated depressed
women or of women with a prescription for an SSRI
that was not redeemed. Variation in the disease sever-
ity, however, is unlikely to explain our observed
RESEARCH
page 4 of 6 BMJ | ONLINE FIRST | bmj.comdifferences between the specific types of SSRI as we
believe that the disease characteristics of women who
use different SSRIs are likely to be comparable in the
study period. The warning on paroxetine from the US
FoodandDrugAdministrationwaspublishedafterthe
exposure period of this study.
15 After this warning the
pattern of SSRIs used during pregnancy is likely to
have changed.
We adjusted for potential confounding factors,
including maternal age and smoking, but all potential
confounders were considered in crude categories.
Residual confounding or unmeasured confounding
might still be present, but the association between the
confounderandheartmalformationneedstobestrong
and specific for individual SSRIs to explain our find-
ings; we don’t know of any such factors.
Weusednationwideregistrieswithalmostcomplete
follow-up of liveborn infants. Induced or spontaneous
abortions might have introduced selection bias if the
drug reduces the survival of a fetus or if exposed
women undergo more intensive screening. For
instance, more intense surveillance among drug users
could result in more prenatal diagnoses and subse-
quentinducedabortions.Thiscouldobscureatrueter-
atogenic effect in studies of liveborn children and bias
our results towards no effect. Late abortion (after
12weeksofpregnancy)becauseofseptalheartdefects,
however, would not be granted in Denmark.
Theinformationonmalformationsfromthehospital
registry is subject to some misclassification. The sensi-
tivity of detection of malformation is expected to be
higherforsevereandvisiblemalformations.Ifthemis-
classification was unrelated to exposure it would in
most cases lead to bias towards no association. If chil-
drenofwomenwithdepressionorwithaspecificphar-
macological treatment for a depression were likely to
be examined more thoroughly than other children,
however, we might have overestimated specific asso-
ciations. The similar overall prevalence of malforma-
tions by the different exposures indicates no such
detection problem.
We used data from a period with an almost fourfold
increase in the proportion of pregnant women who
wereprescribedanSSRI.Aparallelchangeinthedetec-
tionof septal heart defects could lead to bias if calendar
time was not considered—for example, an increased or
improved use of ultrasonography before or after birth
could lead to a false association between SSRIs and
heartdefects.Theestimateschangedonlyslightly,how-
ever, when we adjusted for calendar time in the multi-
variate analyses. Additionally, we found only a small
increase in the prevalence of septal heart defects in the
period that did not parallel the much larger increase in
the use of SSRIs (see figure on bmj.com).
The study was designed to investigate the potential
association between SSRIs and several malformations
with no adjustment for multi-hypotheses testing, and
the findings could potentially have occurred by
chance. Our results, however, are in accordance with
thoseofpreviousstudiesthatuseddifferentmethodsin
other populations. In this light we find that random
error is unlikely to be the only explanation of the
results.
Conclusion and policy implications
SSRIs,particularlycitalopramorsertraline,wereasso-
ciated with an increased prevalence of congenital sep-
talheartdefects.Thelargestprevalencewasfoundafter
redemptions of more than one type of SSRI in the
exposure window, and simultaneous use of different
SSRIs or change in type of SSRI during early preg-
nancy might be problematic. Our results suggest a
class effect of the SSRI on heart defects, and the equi-
vocal results from existing studies could represent dif-
ferences in doses or study population. The
associations, if causal, represent limited risks of an
exposed child having congenital heart defects. Future
studiesneed much larger sample sizes, preferably with
sufficientpowertofurtherinvestigatepotentialassocia-
tions with more severe malformations.
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